|Poll|December 21, 2022
POLL: Which 2022 Psoriasis FDA Approval Were You Most Excited About?
Author(s)Dermatology Times Staff
Click here to answer this week's poll.
Advertisement
Which 2022 Psoriasis FDA Approval Were You Most Excited About?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Priority Review to Zasocitinib for Moderate-to-Severe Plaque Psoriasis
2
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
3
Genetic Study Links Higher BMI to Perceived Facial Aging, but Causality Remains Unproven
4
Defining AD Disease Flares vs Drug Effects: A Comparative Analysis of Phase 3 Systemic Therapy Trials
5